Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 18, 2023 07:00 ET | Source: Jeune Aesthetics, Inc.

Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest

PITTSBURGH, April 18, 2023 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly-owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), today announced treatment of the first...
April 28, 2022 07:00 ET | Source: Jeune Aesthetics, Inc.

Jeune Aesthetics Announces Formation and Members of Scientific Advisory Board

April 28, 2022PITTSBURGH, April 28, 2022 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune Aesthetics”), a wholly-owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS)...
March 22, 2022 07:00 ET | Source: Jeune Aesthetics, Inc.

Jeune Aesthetics Announces Positive Clinical Phase 1 (PEARL-1 Study) Efficacy Results for KB301, an Investigational Gene-based Treatment Designed to Address the Underlying Biology of Aging Skin

Positive proof-of-concept efficacy data supports advancing into Phase 2 studiesAdverse events, associated with injection site reactions, were mild and transitoryConference call to discuss results...
January 13, 2022 16:05 ET | Source: Jeune Aesthetics, Inc.

Jeune Aesthetics Leadership to Present at Octane’s 3rd Annual Aesthetics Tech Summit

PITTSBURGH, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), today announced that Bhushan Hardas, MD, MBA,...
November 19, 2021 07:00 ET | Source: Jeune Aesthetics, Inc.

Jeune Aesthetics to Present Pre-clinical Data Highlighting the Potential of KB303 in Elastin Production at the ASDS 2021 Virtual Meeting

Pre-clincal program evaluated proper formation and deposition of elastic fibers into the skin extracellular matrix in miceKB303 holds potential to be the first-ever directed approach to increase...
August 02, 2021 16:15 ET | Source: Jeune, Inc.

Jeune Aesthetics Announces Initiation of Dosing in Efficacy Cohort of KB301 Phase 1 trial to Assess Improvement in Skin Quality

KB301 is designed to deliver a full-length human type III collagen transgene via intradermal injectionInitial data from this efficacy cohort of the PEARL-1 study is anticipated in 4Q21 PITTSBURGH,...